ENTRY       D10113                      Drug
NAME        Dolutegravir sodium (JAN/USAN);
            Tivicay (TN)
PRODUCT     DOLUTEGRAVIR SODIUM (ViiV Healthcare Company)
            TIVICAY (DOH CENTRAL PHARMACY)
            TIVICAY (RPK Pharmaceuticals)
FORMULA     C20H18F2N3O5. Na
EXACT_MASS  441.1112
MOL_WEIGHT  441.3606
CLASS       Antiviral
             DG03107  Anti-HIV agent
              DG03135  HIV integrase inhibitor
            Metabolizing enzyme substrate
             DG01633  CYP3A/CYP3A4 substrate
              DG02913  CYP3A4 substrate
             DG02924  UGT substrate
              DG03183  UGT1A1 substrate
            Transporter inhibitor
             DG02863  SLC22A2 inhibitor
             DG02864  SLC47A1 inhibitor
REMARK      Therapeutic category: 6250
            ATC code: J05AJ03
            Chemical structure group: DG00667
            Product (DG00667): D10113<JP/US>
            Product (mixture): D10600<JP/US> D11282<JP/US> D11522<JP/US>
EFFICACY    Antiviral, HIV integrase inhibitor
  DISEASE   HIV-1 infection [DS:H01563]
TARGET      HIV-1 integrase [KO:K24803]
  PATHWAY   ko03230(K24803)  Viral genome structure
            ko03240(K24803)  Viral replication
            ko03250(K24803)  Viral life cycle - HIV-1
METABOLISM  Enzyme: UGT1A1 [HSA:54658]; CYP3A4 [HSA:1576]
INTERACTION Transporter inhibition: SLC22A2 [HSA:6582], SLC47A1 [HSA:55244]
STR_MAP     map07053  Anti-HIV agents
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             J ANTIINFECTIVES FOR SYSTEMIC USE
              J05 ANTIVIRALS FOR SYSTEMIC USE
               J05A DIRECT ACTING ANTIVIRALS
                J05AJ Integrase inhibitors
                 J05AJ03 Dolutegravir
                  D10113  Dolutegravir sodium (JAN/USAN) &lt;JP/US&gt;
            USP drug classification [BR:br08302]
             Antivirals
              Anti-HIV Agents, Integrase Inhibitors (INSTI)
               Dolutegravir
                D10113  Dolutegravir sodium (JAN/USAN)
            Therapeutic category of drugs in Japan [BR:br08301]
             6  Agents against pathologic organisms and parasites
              62  Chemotherapeutics
               625  Antivirals
                6250  Antivirals
                 D10113  Dolutegravir sodium (JAN/USAN)
            Drug groups [BR:br08330]
             Antiviral
              DG03107  Anti-HIV agent
               DG03135  HIV integrase inhibitor
                DG00667  Dolutegravir
                 D10113  Dolutegravir sodium
             Metabolizing enzyme substrate
              DG01633  CYP3A/CYP3A4 substrate
               DG02913  CYP3A4 substrate
                DG00667  Dolutegravir
                 D10113  Dolutegravir sodium
              DG02924  UGT substrate
               DG03183  UGT1A1 substrate
                DG00667  Dolutegravir
                 D10113  Dolutegravir sodium
             Transporter inhibitor
              DG02863  SLC22A2 inhibitor
               DG00667  Dolutegravir
                D10113  Dolutegravir sodium
              DG02864  SLC47A1 inhibitor
               DG00667  Dolutegravir
                D10113  Dolutegravir sodium
            Drug classes [BR:br08332]
             Antiviral
              DG03107  Anti-HIV agent
               D10113  Dolutegravir sodium
            Antimicrobials [BR:br08307]
             Antivirals
              Genome replication inhibitor
               HIV integrase inhibitor
                D10113  Dolutegravir sodium (JAN/USAN) &lt;JP/US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D10113
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D10113
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D10113
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D10113
            Drug metabolizing enzymes and transporters [br08309.html]
             Drug metabolizing enzymes
              D10113
             Drug transporters
              D10113
            Pharmacogenomic biomarkers [br08341.html]
             Polymorphisms and mutations affecting drug response
              D10113
            Drug groups [BR:br08330]
             Antiviral
              DG03107  Anti-HIV agent
               DG03135  HIV integrase inhibitor
                DG00667  Dolutegravir
             Metabolizing enzyme substrate
              DG01633  CYP3A/CYP3A4 substrate
               DG02913  CYP3A4 substrate
                DG00667  Dolutegravir
              DG02924  UGT substrate
               DG03183  UGT1A1 substrate
                DG00667  Dolutegravir
             Transporter inhibitor
              DG02863  SLC22A2 inhibitor
               DG00667  Dolutegravir
              DG02864  SLC47A1 inhibitor
               DG00667  Dolutegravir
            Antimicrobials abbreviations [BR:br08327]
             Antivirals
              Genome replication inhibitor
               HIV integrase inhibitor
                DG00667  Dolutegravir
DBLINKS     CAS: 1051375-19-9
            PubChem: 135626831
            ChEBI: 76007
            LigandBox: D10113
ATOM        31
            1   C8y C    21.5600  -21.8400
            2   N4y N    21.5600  -20.4400
            3   C8x C    22.7500  -19.7400
            4   C8y C    24.0100  -20.4400
            5   C8y C    24.0100  -21.8400
            6   C8y C    22.7500  -22.5400
            7   C5x C    20.3700  -22.5400
            8   N1y N    19.1100  -21.8400
            9   C1y C    19.1100  -20.4400
            10  C1x C    20.3700  -19.7400
            11  C1y C    17.8500  -22.5400
            12  C1x C    16.6600  -21.8400
            13  C1x C    16.6600  -20.4400
            14  O2x O    17.8500  -19.7400
            15  O5x O    20.3700  -23.9400
            16  O1a O    22.7500  -23.9400 #-
            17  O5x O    25.2000  -22.5400
            18  C5a C    25.2000  -19.7400
            19  N1b N    26.3900  -20.4400
            20  O5a O    25.2000  -18.3400
            21  C1b C    27.5800  -19.7400
            22  C8y C    28.7700  -20.4400
            23  C8x C    29.9600  -19.7400
            24  C8x C    31.2200  -20.4400
            25  C8y C    31.2200  -21.8400
            26  C8x C    30.0300  -22.5400
            27  C8y C    28.7700  -21.8400
            28  X   F    27.5800  -22.5400
            29  X   F    32.4100  -22.5400
            30  C1a C    19.1100  -23.2400
            31  Z   Na   24.6400  -24.5700 #+
BOND        33
            1     1   2 1
            2     2   3 1
            3     3   4 2
            4     4   5 1
            5     5   6 1
            6     1   6 2
            7     1   7 1
            8     7   8 1
            9     8   9 1
            10    9  10 1
            11    2  10 1
            12    8  11 1
            13   11  12 1
            14   12  13 1
            15   13  14 1
            16    9  14 1
            17    7  15 2
            18    6  16 1
            19    5  17 2
            20    4  18 1
            21   18  19 1
            22   18  20 2
            23   19  21 1
            24   21  22 1
            25   22  23 2
            26   23  24 1
            27   24  25 2
            28   25  26 1
            29   26  27 2
            30   22  27 1
            31   27  28 1
            32   25  29 1
            33   11  30 1 #Down
///
